NMN: does it actually work, and should you take it?

The honest answer upfront

NMN (nicotinamide mononucleotide) is one of the most heavily marketed longevity supplements of the past decade — and one of the most overhyped. Yes, it raises blood NAD+ levels in humans (Grade B evidence). No, there is no human evidence that this translates to reversing ageing or extending lifespan (Grade D). Our verdict: skip it for now — not because it is definitively useless, but because the proof does not yet match the price.

What NMN is

NMN is a precursor to NAD+ (nicotinamide adenine dinucleotide), a coenzyme involved in cellular energy production, DNA repair, and the activity of sirtuins — proteins linked to metabolic health and ageing in animal models. NAD+ levels decline with age, and the hypothesis driving NMN's popularity is that replenishing them could slow or reverse age-related decline.

The logic is mechanistically plausible. In animal models — mostly mice — NMN supplementation has produced impressive results: improved insulin sensitivity, better endurance, reduced markers of inflammation, and extended healthspan. But mice are not people, and this is where the hype has consistently outrun the evidence.

Does it work? The evidence, graded

Raises blood NAD+ — Grade B

This is the one claim NMN reliably delivers. Multiple short-term human trials have confirmed that oral NMN at doses of 250–900 mg/day significantly raises circulating NAD+ levels. A 2023 review published in Advances in Nutrition (covering all available human RCTs) confirmed consistent NAD+ elevation across different doses and populations. This is not disputed.

What remains entirely open is whether higher blood NAD+ translates into any meaningful health or performance outcome in humans over the timescales most people care about.

Physical function and endurance — Grade C

A small number of short-term human trials have reported modest improvements in aerobic capacity and physical performance. One 2021 trial in recreational runners found that NMN improved muscle oxygen utilisation compared to placebo. Another study in older adults reported improvements in gait speed and muscle strength. These are genuinely interesting signals — but every trial to date is small (typically under 50 participants), short (six to twelve weeks), and funded or conducted by groups with commercial interests in the outcome. They are hypothesis-generating, not conclusive. Grade C: limited, early-stage, requires replication.

Reversing ageing or extending lifespan in humans — Grade D

Zero human evidence. The longevity claims attached to NMN come almost entirely from animal studies, most of which used very high doses relative to body weight that do not translate directly to a human equivalent. No long-term human RCT exists. The promise is real enough to fund research; the proof is not there yet.

How to take it — if you choose to

Human trials have used 250–900 mg/day, typically as a single morning dose, with or without food. There is no established loading phase. Most commercially available products are capsules or sublingual tablets, with some manufacturers claiming sublingual absorption is superior — this has not been convincingly demonstrated in head-to-head trials.

Be aware that because NMN's UK/EU novel food status is unsettled, the supply chain is unregulated in a meaningful sense. Products vary widely in purity and actual NMN content. If you do purchase, prioritise brands with independent third-party testing and clear certificates of analysis — not self-declared lab results on the brand's own website.

Who might consider it — and who should avoid it

Who might consider it: Adults over 50 with a strong interest in longevity science, a well-optimised diet and training base, and the budget to experiment with early-stage supplements while accepting the evidence limitations. NMN is most defensible as a speculative, optional addition once all the fundamentals are locked in.

Who should avoid it: Anyone pregnant or breastfeeding; anyone with a personal or family history of cancer (NAD+ supports cellular repair and proliferation — the theoretical concern here has not been resolved); anyone on medication without first consulting their GP. This is not a supplement for teenagers or young adults chasing muscle or fat loss — there are far better-evidenced options for those goals (see creatine and whey protein).

Under 18s: no data, no justification.

Safety and regulatory cautions

Short-term human trials (up to roughly 12 weeks) have found NMN well tolerated at doses up to 900 mg/day, with no serious adverse events in healthy adults. Mild GI discomfort has been reported occasionally.

The bigger safety concern is not acute toxicity but what we do not yet know. Long-term human data simply does not exist. The theoretical cancer-biology concern — that boosting NAD+ could support tumour cell metabolism and proliferation — remains unresolved in the literature. It is not a proven risk, but it is not a dismissed one either. Anyone with a cancer history should not self-supplement without specialist advice.

On the regulatory side: in the UK and EU, NMN has not been authorised as a novel food. This means many products are technically in a legal grey zone, and the manufacturing and quality standards applied can be inconsistent. This is not a trivial concern — supplements in regulatory limbo often suffer from poor quality control.

How to buy NMN well — if you go ahead

If you decide to experiment despite the Grade D longevity evidence, apply the same discipline you would to any unregulated market:

• Demand a certificate of analysis (CoA) from an independent third-party laboratory — not a brand-owned lab.
• Look for brands that publish heavy-metal testing results.
• Avoid products that make explicit anti-ageing, disease-prevention or lifespan-extension claims — these are not supported by evidence and may indicate a willingness to overreach elsewhere.
• Keep doses within the human trial range (250–500 mg/day is a reasonable starting point; 900 mg/day is the high end of studied doses).

The 95% reminder

NMN is the textbook example of a supplement that can absorb a lot of time, money and mental energy that would be better spent on the fundamentals. Consistent training, adequate protein (1.6–2.2 g/kg/day), quality sleep, and a structured programme are responsible for the overwhelming majority of your health and physical performance gains. Supplements — including the well-evidenced ones — account for roughly 5%.

Before you spend money on a Grade D longevity supplement, make sure your training programme is actually optimised. Book a free consultation and we will show you exactly where the real gains are hiding. Or start with the free Blueprint quiz to get a personalised assessment in under three minutes.

For supplements that are actually worth it at your stage, compare creatine (Grade A, strong evidence, £1–2/month) — the contrast is instructive. If healthy ageing is the goal, omega-3 fish oil and vitamin D have far stronger evidence bases and cost a fraction of the price.

The verdict

NMN is scientifically interesting and mechanistically plausible. It reliably raises blood NAD+. But at the current state of evidence — no meaningful human lifespan or ageing data, unsettled UK/EU regulatory status, and unknown long-term safety — the honest recommendation is to skip it. Put your budget into training, food quality, and well-evidenced fundamentals. Revisit NMN in two to three years when the human trial data matures.